Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient

• US 20070178591A1
• Filed: 06/25/2004
• Published: 08/02/2007
• Est. Priority Date: 06/25/2004
• Status: Abandoned Application

• Current Assignee: ASKA Pharmaceutical Company Limited, NC Medical Research Inc. (e-solutions, Inc. /Japan/), Mitsui Sumitomo Insurance Company Limited (Ms&Ad Insurance Group Holdings Incorporated)
• Original Assignee: ASKA Pharmaceutical Company Limited, Hitachi, Ltd., Mitsui Sumitomo Insurance Company Limited (Ms&Ad Insurance Group Holdings Incorporated), Renomedix Institute, Inc.
• Inventors: Hamada, Hirofumi, Honmou, Osamu
• Application Number:
  US10/562,202
• Publication Number:
  US 20070178591A1
• Time in Patent Office: Days
• US Class Current: 435/365
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10345 Special targeting system for viral vectors
• CPC Class Codes: C12N 2810/405 Vectors comprising RGD peptide
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Claims

1. A cranial nerve disease therapeutic agent for in vivo administration, comprising a mesenchymal cell as an active ingredient.

2. The agent of claim 1, wherein the cranial nerve disease is cerebral infarction.

5. The agent of claim 1, wherein the in vivo administration is intravenous.

6. The agent of claim 1, wherein the mesenchymal cell is:

(a) a mesenchymal cell introduced with a BDNF gene, PLGF gene, GDNF gene, or IL-2 gene;

or

(b) an immortalized mesenchymal cell introduced with an hTERT gene.

7. The agent of claim 1, wherein the mesenchymal cell is a mesenchymal stem cell.

8. The agent of claim 1, wherein the mesenchymal cell is a bone marrow cell, a cord blood cell, or a peripheral blood cell.

9. A method for treating a cranial nerve disease comprising the in vivo administration to a patient of a therapeutically effective amount of the agent of claim 1.

10. The method of claim 9, wherein the bone marrow cell is an autologous cell of the patient.

11. The method of claim 9, wherein the cranial nerve disease is cerebral infarction.

12. The method of claim 9, wherein the in vivo administration is intravenous administration.

13. The method of claim 9, wherein the mesenchymal cell is a bone marrow cell, a cord blood cell, or a peripheral blood cell.

3. An agent for in vivo administration, exhibiting neuroprotection and comprising a mesenchymal cell as an active ingredient.

4. An agent for in vivo administration, exhibiting cranial nerve regeneration and comprising a mesenchymal cell as an active ingredient.